背景:幽门螺杆菌感染及其相关疾病是一个重要的全球健康问题。不能使用阿莫西林的患者构成了治疗挑战,需要替代药物。初步研究表明,头孢呋辛具有根除幽门螺杆菌感染的潜力,缺乏关于头孢呋辛使用的全面综述文章。
方法:本研究进行了全面系统的文献综述和综合。在PubMed进行了全面系统的搜索,WebofScience,EMBASE,中国国家知识基础设施,中国生物医药光盘,和万方数据截至2024年1月13日。搜索策略使用以下关键字:(头孢呋辛)和(幽门螺杆菌或线虫螺杆菌或幽门弯曲杆菌或幽门弯曲杆菌亚种。英文和中文出版物的幽门螺杆菌或幽门弯曲杆菌或幽门螺杆菌或Hp)。来自五个不同国家或地区的16项研究被纳入最终文献综述。
结果:分析结果表明幽门螺杆菌对头孢呋辛敏感,与阿莫西林相似的耐药率相对较低。含有头孢呋辛的方案显示出良好的根除率,与含阿莫西林的方案相当。关于安全,含头孢呋辛的根除方案的不良反应发生率与含阿莫西林的方案或其他铋四联方案相当。青霉素过敏患者的过敏反应没有显着增加。关于合规,研究一致报告含有头孢呋辛的方案的高依从率.
结论:头孢呋辛可以替代阿莫西林治疗青霉素过敏患者,疗效满意。安全,和合规。
BACKGROUND: Helicobacter pylori infection and its associated diseases represent a significant global health concern. Patients who cannot use amoxicillin pose a therapeutic challenge and necessitate alternative medications. Preliminary research indicates that cefuroxime demonstrates promising potential for eradicating H. pylori infection, and there is a lack of comprehensive
review articles on the use of cefuroxime.
METHODS: This study conducts a thorough systematic literature
review and synthesis. A comprehensive systematic search was conducted in PubMed, Web of Science, EMBASE, China National Knowledge Infrastructure, China Biology Medicine disc, and Wanfang Data up to January 13, 2024. The search strategy utilized the following keywords: (Cefuroxime) AND (Helicobacter pylori OR Helicobacter nemestrinae OR Campylobacter pylori OR Campylobacter pylori subsp. pylori OR Campylobacter pyloridis OR H. pylori OR Hp) for both English and Chinese language publications. Sixteen studies from five different countries or regions were included in final literature
review.
RESULTS: Analysis results indicate that H. pylori is sensitive to cefuroxime, with resistance rates similar to amoxicillin being relatively low. Regimens containing cefuroxime have shown favorable eradication rates, which were comparable to those of the regimens containing amoxicillin. Regarding safety, the incidence of adverse reactions in cefuroxime-containing eradication regimens was comparable to that of amoxicillin-containing regimens or other bismuth quadruple regimens, with no significant increase in allergic reactions in penicillin-allergic patients. Regarding compliance, studies consistently report high compliance rates for regimens containing cefuroxime.
CONCLUSIONS: Cefuroxime can serve as an alternative to amoxicillin for the patients allergic to penicillin with satisfactory efficacies, safety, and compliance.